TY - JOUR
T1 - High rate of over-staging of Barrett's neoplasia with endoscopic ultrasound
T2 - Systemic review and meta-analysis
AU - Qumseya, Bashar J.
AU - Bartel, Michael J.
AU - Gendy, Sherif
AU - Bain, Paul
AU - Qumseya, Amira
AU - Wolfsen, Herbert
N1 - Publisher Copyright:
© 2018 Editrice Gastroenterologica Italiana S.r.l.
PY - 2018/5
Y1 - 2018/5
N2 - Background: The use of endoscopic ultrasound (EUS) to stage patients with Barrett's esophagus (BE) with suspected neoplasia is controversial due to high rates of over-staging. However, this rate of over-staging has not been adequately investigated or quantified. Aim: To determine the rate of over-staging related EUS in this population. Methods: Search included Medline, Embase, Web of Science, and Cochrane Central ending on 9/30/2016. The primary effect-estimate of interest was the false positive rate of advanced disease on EUS at the tumor level (T1a vs. T1b). Secondary outcomes included false detection rate, false negative rate, accuracy, sensitivity, and specificity. Study heterogeneity was assessed using the I2 and Cochrane's Q. Results: Of 1872 studies, 11 met our inclusion criteria totaling 895 patients. Based on random effects models, the pooled FPR for advanced disease was 9.1% ([6.5–12.5%], p < 0.001). Tests of heterogeneity showed no significant heterogeneity for this outcome. The pooled false negative rate was 9.2% [95%CI: 4.7–17.3%], p < 0.01. Overall, the pooled accuracy of EUS results in BE neoplasia patients was low at 74.6% [58.7–85.8%], p = 0.004. Conclusions: The use of EUS in BE patients with dysplasia and early neoplasia results in a large proportion of patients falsely over-staged and under-staged.
AB - Background: The use of endoscopic ultrasound (EUS) to stage patients with Barrett's esophagus (BE) with suspected neoplasia is controversial due to high rates of over-staging. However, this rate of over-staging has not been adequately investigated or quantified. Aim: To determine the rate of over-staging related EUS in this population. Methods: Search included Medline, Embase, Web of Science, and Cochrane Central ending on 9/30/2016. The primary effect-estimate of interest was the false positive rate of advanced disease on EUS at the tumor level (T1a vs. T1b). Secondary outcomes included false detection rate, false negative rate, accuracy, sensitivity, and specificity. Study heterogeneity was assessed using the I2 and Cochrane's Q. Results: Of 1872 studies, 11 met our inclusion criteria totaling 895 patients. Based on random effects models, the pooled FPR for advanced disease was 9.1% ([6.5–12.5%], p < 0.001). Tests of heterogeneity showed no significant heterogeneity for this outcome. The pooled false negative rate was 9.2% [95%CI: 4.7–17.3%], p < 0.01. Overall, the pooled accuracy of EUS results in BE neoplasia patients was low at 74.6% [58.7–85.8%], p = 0.004. Conclusions: The use of EUS in BE patients with dysplasia and early neoplasia results in a large proportion of patients falsely over-staged and under-staged.
KW - Barrett's esophagus
KW - Endoscopic ultrasound
KW - Esophageal adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85044334520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044334520&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2018.02.005
DO - 10.1016/j.dld.2018.02.005
M3 - Review article
AN - SCOPUS:85044334520
SN - 1590-8658
VL - 50
SP - 438
EP - 445
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 5
ER -